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IL-10/STAT3 pathwayIn spite of the numerous reports implicating MafB transcription factor in the molecular control of monocyte–
macrophage differentiation, the precise genetic program underlying this activity has been, to date, poorly under-
stood. To clarify this issue, we planned a number of experiments that were mainly conducted on human primary
macrophages. In this regard, a preliminary gene function study, based onMafB inactivation and over-expression,
indicatedMMP9 and IL-7R genes as possible targets of the investigated transcription factor. Bioinformatics anal-
ysis of their promoter regions disclosed the presence of several putative MARE elements and a combined ap-
proach of EMSA and luciferase assay subsequently demonstrated that expression of both genes is indeed
activated by MafB through a direct transcription mechanism. Additional investigation, performed with similar
procedures to elucidate the biological relevance of our observation, revealed that MafB is a downstream target
of the IL-10/STAT3 signaling pathway, normally inducing the macrophage de-activation process. Taken together
our data support the existence of a signaling cascade by which stimulation of macrophages with the IL-10 cyto-
kine determines a sequential activation of STAT3 and MafB transcription factors, in turn leading to an up-
regulated expression ofMMP9 and IL-7R genes.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
From an evolutionary point of view, macrophages are considered
the most primitive cells since related cell types are observed from pro-
tozoa up to complex multicellular eukaryotic organisms [1]. Several
molecules, such as transcription factors (TFs), growth factors, vitamins,
hormones and cytokines, are involved in the regulation of monocyte–
macrophage differentiation to assure, across species, the presence of
these cells and their functions in innate and adaptive immunity [2]. A
large body of evidence highlighted the crucial role played by transcrip-
tional regulation in the monocyte maturation program, demonstratingssay; HSCs, hematopoietic stem
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siderable number of myeloid TFs, belonging to a limited set of protein
families (MAF, Mitf-Tfe, HOX, PPAR, C/EBP, IRF, EGR) [2–8]. Inside this
intricate network, MafB may be considered a key player in the genetic
control of normal monocytopoiesis. MafB is a leucine zipper DNA bind-
ing protein belonging to theMaf family and it shows binding activity to
theMaf responsive element (MARE) and to the 5′AT-richhalf-MARE [9],
contained in the promoter regions of target genes. In addition, MafB
supports either transcription activation or repression depending on
the interacting dimerization partner [10]. This TF is evolutionary con-
served [11–13] and several reports indicate that, in human hematopoi-
esis, its expression is monocyte speciﬁc. In fact, data obtained in our
laboratory demonstrated that: 1) MafB is highly expressed in mono-
blasts, monocytes and, accordingly, in monoblastic cell lines (THP1,
U937 and Kasumi-1) [5,14]; 2) virally mediated MafB transduction of
human hematopoietic progenitors determines a massive induction of
monocyte–macrophage differentiation, coupled to a strong inhibition
of erythroid commitment [5]; and 3) MafB is a direct target of two
monocyte–macrophage related TFs, i.e. Hox-A10 [6] and TFE3 [15]. In
addition, data reported in literature underlined that high levels of
MafB expression are able to activate the macrophage maturation pro-
gram at the expense of dendritic cell (DC) differentiation [16,17] and
that its down-regulation is also required for osteoclast differentiation
of myeloid cells [18–20]. Nevertheless, the genetic program controlled
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regard, preliminary results were provided by our research group
through the analysis of the gene expression proﬁle obtained in hemato-
poietic stem cells virally transducedwith aMafB cDNA [5]. The results of
these experiments revealed thatMafB is able to control the gene expres-
sion of about one hundred genes, involved in monocyte differentiation
and macrophage activation. In addition, the analysis of transcriptomes
obtained by normal monoblasts [14] and Hox-A10-transduced hemato-
poietic progenitors [5,6] disclosed a recurrent co-expression of MafB
with severalmacrophage phenotypic markers that might be considered
putative MafB primary response genes. Inside this gene list we focused
our attention on two interesting genes: Matrix Metallo-Proteinase 9
(MMP9) and Interleukine 7 Receptor (IL-7R). MMP9 is a well-known
molecule involved in several aspects of monocyte biology, including
monocyte differentiation and polarization [21,22], and it is also up-
regulated in THP1 cells treated with retinoic acid, another model of
monocyte differentiation characterized by high expression of MafB
[23]. In addition, in a previous paper byMontanari et al. [14]we demon-
strated that, in the comparison with primary myeloblasts, monoblasts
precursors were characterized by a large amount of IL-7R transcript,
suggesting it as a novel differentiation marker of human normal
monocytopoiesis. In light of these considerations, the rationale of the
present study is to demonstrate that MMP9 and IL-7R genes are tran-
scriptionally regulated by MafB through the identiﬁcation of speciﬁc
MAREelementswithin their promoter regions and that this genetic pro-
gram is involved in the anti-inﬂammatory process. Interestingly, the
results described here allowed us to state that MafB is a downstream
target of the IL-10/STAT3 signaling pathway directly involved in the
macrophage de-activating process.
2. Material and methods
2.1. Human hematopoietic cells
THP1monoblastic cell line, obtained fromATCC (Rockville,MD),was
cultured in RPMI 1640medium (EuroClone, Devon, UK), supplemented
with 10% heat inactivated fetal bovine serum (BioWhittaker,
Walkersville, MD; FBS Brazilian origin, Cat. N. DE14-801F, Lot. N.
1SB004) and 1 mM L-glutamine (EuroClone). THP1 cells were treated
with phorbol 12-myristate 13-acetate (PMA; Sigma Chemical Co, St.
Louis, MO) at 1.6 nM concentration for 48 h.
Human CD34+ stem–progenitor cells and CD14+monocytes were
puriﬁed, respectively, from umbilical cord blood and adult peripheral
blood specimens, as already described [5,14,24]. Human samples were
recruited at the blood transfusion division of Policlinico of Modena,
upon a written informed consent of voluntary donors. Cell positive se-
lections were carried out, according to the manufacturer's protocol, by
using the immune–magnetic systems “EasySep Human CD34+
Selection Kit” and “EasySep Human CD14 Selection Kit”, both provided
by STEMCELL Technologies. Primary cells (stem/progenitors and
monocytes) were cultured in IMDM (EuroClone) supplemented with
10% heat inactivated human serum AB (Biowittaker) and 1 mM
L-glutammine (EuroClone). Classical monocyte activation was ob-
tained by a 24 h treatment with a combination of 100 ng/ml LPS
(Difco Laboratories) and 20 ng/ml IFNγ (Roche Diagnostics, Mannheim,
Germany), alternative polarization was carried out by a 72 h stimula-
tion with 20 ng/ml IL-4 (R&D System); macrophage de-activation was
achieved by treatment with a 50 ng/ml concentration of IL-10 cytokine
(Miltenyi Biotec, Auburn, CA, USA) for up to 72 h.
2.2. Retroviral vectors construction, cell transduction and puriﬁcation
Construction of LXIΔN and LMafBIΔN retroviral vectors as well as
retroviral transduction of CD34+ progenitor cells were performed as
previously reported [5,6]. Transduced CD34+ cells were NGFR puriﬁed
at day 7 of liquid culture by using a mouse anti-human p75-NGFRmonoclonal antibody (Ab) (BD Biosciences PharMingen, San Diego,
CA, USA) and “Easy SepDo It Yourself” selection kit (STEMCELL Technol-
ogies). Transduced and puriﬁed progenitors were maintained in liquid
culture until day 14 in the described conditions and then lysed for
RNA extraction and subsequent molecular analysis.
2.3. Gene silencing
MafB silencing was achieved in THP1 monoblastic cells and in
human normal monocytes using a 100 nM concentration of a mixture
of three pre-designed siRNA duplexes provided by Sigma-Aldrich
(Sigma Aldrich, St. Louis, MO, USA; Oligo name: SASI_Hs01_00197232;
SASI_Hs02_00339624; SASI_Hs02_00339625). Two rounds of nucleo-
fection procedure, performed according to the Amaxa Nucleofector
Technology, were carried out on 5 × 106 cells every 24 h and, following
a 48 h period, a dose of 1.6 nMof PMAor 50 ng/ml of IL-10was added for
additional 24 h, respectively to culture medium of THP1 cells or normal
monocytes. Each experiment included a mock and a negative control
represented by a non-targeting siRNA synthesized by Sigma-Aldrich in
order to exclude non-speciﬁc effects of siRNA nucleofection. Quantita-
tive real time PCR (QRT-PCR) and Western blot techniques were then
used to evaluate MafB silencing upon PMA or IL-10 treatment.
2.4. RNA puriﬁcation and quantitative RT-PCR
Total cellular RNAs were extracted by means of Qiagen total RNA
puriﬁcation kits (Qiagen, Valencia, CA) and then analyzed by NanoDrop
2000 spectrophotometer (Thermo Fisher Scientiﬁc,Waltham,MA, USA)
to evaluate RNA integrity and concentration. QRT-PCR was carried out
by an ABI PRISM 7900 sequence detection system (Applied Biosystems)
on total RNAs (100 ng) reverse transcribed using the High Capacity
cDNA Archive Kit (Applied Biosystems), according to the
manufacturer's instructions. Each cDNA sample was run in triplicate
for targets (MAFB, MMP9, IL-7R, IL-6, TNF-α, IL-1RA, MRC1, CD163)
and for GAPDH endogenous control using primers and probes supplied
by Applied Biosystems as pre-made solutions and the FastStart Univer-
sal Probe Master Mix (Roche Diagnostics). Quantiﬁcation of QRT-PCR
signalswas performed using the (2−ΔΔCt)method [25] which calculates
relative changes in gene expression of the target gene normalized to the
GAPDH endogenous control and relative to a calibrator sample. The
values obtained were represented in terms of relative quantity of
mRNA level variations.
2.5. Protein extract preparation and western blot analysis
Total protein extracts were obtained using a small volume of lysis
buffer (50 mM TRIS pH 7.8, 400 mM NaCl, 1% NP-40, 1 mM PMSF, 1×
Protease Inhibitor Cocktail), followed by incubation on ice for 30 min
and centrifugation for additional 30 min at high speed. 30 μg of protein
extracts was then loaded onto 10% SDS-polyacrylamide gel electropho-
resis and electroblotted to nitrocellulose sheets. Blotted membranes
were pre-blocked for 1 h at room temperature (RT) in blocking solution,
composed by 5% nonfat milk (Regilait, Saint-Martin-Belle-Roche,
France) in 0.05% TBST or by 3% nonfat milk and 2% BSA (Sigma Aldrich,
St. Louis, MO, USA) in TBST 0.1%, according to antibodies speciﬁcity. The
following rabbit anti-human primary antibodies were used at concen-
trations recommended by the manufacturer's instruction: MafB poly-
clonal Ab (Sigma-Aldrich), MMP9 monoclonal Ab and polyclonal IL-7R
alpha Ab (Abcam, Cambridge, UK). As a secondary antibody, conjugated
to horse-radish peroxidase, we used a goat anti mouse IgG (Santa Cruz
Biotechnology) and goat anti-rabbit IgG (Cell Signaling Technology) at
1:10,000 and 1:3000 dilutions, respectively. To normalize analyzed pro-
tein samples, a mouse anti-human pan actin monoclonal Ab (Sigma
Aldrich) and a rabbit anti-human vinculin polyclonal Ab (Millipore
Corporation, Billerica, MA, USA) were used. Detection of Western blot
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cent substrate (Cyanagen S.r.l., Bologna, Italy).
2.6. Flow cytometry analysis
Surface antigen expressionwas detectedusing the followingMoAbs:
anti-NGFR conjugated to ﬂuorescein isothiocyanate (FITC), phycoery-
thrin (PE)-conjugated IL-7R, PE-conjugated MRC1 (Miltenyi Biotec),
biotin-conjugated CD163 (BMA Biomedicals AG, Augst, Switzerland),
and TRICOLOR-conjugated streptavidin (Caltag Laboratories, Burlin-
game, CA). Antibodies incubations were carried out as described [24].
Analysis was performed in terms of positivity percentage by using a
Coulter Epics XL-MCL (Coulter Electronics, Hialeah, FL) ﬂow cytometer.
2.7. Plasmid expression vectors
A Flag tagged MafB cDNA fragment, obtained as already described
[5], was cloned in the EcoRI site of pcDNA3.1 plasmid (Invitrogen,
Carlsbad, CA, USA) resulting in pcDNA3.1FlagMafB construct. The
pCMVSTAT3 expression vector was instead supplied by OriGene Tech-
nologies (Rockville, MD). The pT81Luc vectors [26], containing MAFB
or STAT3 binding elements, were generated as described below. The fol-
lowing single-strand oligomers and their complements were used:
MMP9 MARE probe: 5′-GATCGACCCCCTGAGTCAGCACTT-3′;
IL-7R MARE probe: 5′-GATCGTAGGGACTGACTCAGCACATG-3′;
STAT3 ENHANCER 1 probe: 5′-GATCGCTGCTTCTCAGAAGACC-3′;
STAT3 ENHANCER 2 probe: 5′-GATCGACCTTCCAGGAAACCC-3′.
The double strand oligomers, obtained by annealing single-strand
oligonucleotides modiﬁed at the 5′ end with the BamH1 and SalI over-
hang restriction sites, were inserted into the BamHI/SalI digested
pT81Luc vector, upstream to a minimal promoter and the luciferase re-
porter gene. According to these cloning strategies, the following con-
structs were generated: pT81LucMMP9MARE, pT81LucIL-7RMARE,
pT81LucSTAT3Enhancer1 and pT81LucSTAT3Enhancer2. Nucleotide
sequence analysis of the plasmids demonstrated that binding sequences
had been inserted as single-copy oligomer.
2.8. EMSA and reporter gene assays
The double strand MARE elements, reported in Table 1, were 5′ end
labeled byγ32P-ATP (6000 Ci/mmol, GEHealthcare Europe GmbH, Frei-
burg), T4 polynucleotide kinase (New England Biolabs, Ipswich, MA)
and puriﬁedwithMicroSpin G-25 Columns (GE Healthcare). Themobil-
ity shift reactionswere carried out as described [6]. 2 μl of “in vitro” tran-
scribed/translated Flag-MafB protein, produced by using the “TnT Quick
Coupled Transcription/Translation System” (Promega, Madison, WI) in
the presence of pcDNA3.1FlagMafB construct as template, was added
to the reaction in a total volume of 20 μl. A negative control (Mock), rep-
resented by TNT Quick Master Mix incubated with pcDNA3.1 empty
vector as template, was also included. Super-shift was obtained by
adding, to the gel shift mix, 1 μg of FlagM2MouseMonoclonal antibody
(Sigma Aldrich). Binding reactions were incubated at RT for 30min andTable 1
List of putative MARE elements used as probe in EMSA assays.
Probe name Sequence 5′–3′ Position from “+1” (bp)
MARE consensus 5′-TGCTGAC/GTCAGCA-3’
MMP9 MARE 5′-CCCTGAGTCAGCA-3′ −84
MMP9 MARE mutated 5′-CCCTGACTCAGCT-3′
IL-7R MARE 5′-GACTGACTCAGCA-3′ −4288
IL-7R MARE mutated 5′-GACTGAGTCAGGA-3′
This table reports the putative MafB binding sites, and its mutated forms, identiﬁed in
MMP9 and IL-7R promoter regions and used in EMSA experiments. Inside the putative
MARE motives, divergent nucleotides are indicated by bold font whereas mutated
nucleotides are underlined.resolved using a non-denaturing 4% polyacrylamide gel in 0.5× TBE,
pre-run for 1 h at RT. Finally the gelwas ﬁxed, vacuumdried, and expose
to X-ray ﬁlms.
2.9. Luciferase reporter assay
Luciferase transactivation assays were carried out in HEK293 cells as
already described [6]. Transient transfection was conducted in 24-well
plate with TRANSIT 2020 reagent (Mirus Bio LLC, Madison, Wisconsin),
using 200 ng of pT81Luc reporter plasmids, 50 ng of pcDNA3FlagMafB
or pCMVSTAT3, 200 ng of pCMVβ-galactosidase (Clontech Laboratories,
Inc. Mountain View, CA, USA) to normalize for transfection efﬁciency,
and a carrier plasmid to maintain a total DNA concentration of 800 ng.
Following 48 h of incubation, cells were lysed according to standard
protocols for β-galactosidase and luciferase enzymatic assays.
2.10. Chromatin immune-precipitation
Two different ChIP experiments were developed in the present
study in order to verify MafB binding to MMP9 and IL-7R target genes
and, subsequently, to evaluate STAT3 binding to MafB promoter region.
All the experiments were conducted in human monocytes under
normal culture conditions or upon treatment with IL-10 cytokine at
50 ng/ml concentration for 24 h. 3 × 107 cells were used for this
purpose. Although the aims of ChIPs were different, the experimental
settings adopted were similar and are described below. Human mono-
cyteswere cross-linked, lysed andwashed according to standard proto-
cols. The samples were then sonicated in order to shear DNA to
100–1000 bp fragments and the chromatin was then immune-
precipitated by using 5 μg of the following Abs: goat polyclonal anti-
MafB Ab (Santa-Cruz), rabbit polyclonal anti-STAT3 Ab (Millipore) or
anti-Flag Ab (Sigma Aldrich) used as a control. Subsequently, the en-
richment for MAFB- or STAT3-bound sequence was veriﬁed by semi-
quantitative PCRusingprimers amplifying the genomic region spanning
the putativeMARE elements or the STAT3 enhancers. In addition, to fur-
ther validate the speciﬁcity ofMAFB/STAT3binding on the respective el-
ements, PCR ampliﬁcations were carried out on the microsatellite
region localized on chromosome 3, selected as negative control region.
PCR reactions were performed using 1.5 μl of immuno-precipitated
DNA with 0.3 mM dNTPs, 150 ng of both primers (see Table 1 Supple-
mentary material), 5× Go-Taq buffer and 2 units of Go Taq (Promega)
in a 50 μl volume. The ethidium bromide gel images were analyzed by
Image J software (National Institute of Health) and thepercentage of en-
richment was calculated from the ratio between the amounts of PCR-
ampliﬁed MAFB- or STAT3-bound DNA in ChIP samples and in input
chromatin. Inside the same experimental design, three replicates were
performed and data were indicated as mean ± s.e.m.
2.11. Statistical analysis
All experiments were repeated at least three times and results were
presented as mean ± s.e.m. values. Pairwise comparisons were carried
out using student's t-test procedurewhereasmultiple comparisons anal-
ysis were performed by one-way analysis of variance (ANOVA) followed
by Newman–Keuls post-hoc test by using the GraphPad Software [27].
Results of statistical analysiswere considered signiﬁcantwhen exhibiting
p-values ≤0.05 and are indicated by asterisks. *p b 0.05; **p b 0.01.
3. Results
3.1. Analysis of MafB, MMP9 and IL-7R gene expression
As described in the Introduction section, the co-expression of MafB
with IL-7R and MMP9 genes has been observed in various primary he-
matopoietic cell contexts analyzed in our laboratory [5,6,14]. Neverthe-
less, to conﬁrm this issue, we performed preliminary experiments in
Fig. 2. Evaluation of MAFB, MMP9 and IL-7R genes in CD34+ hematopoietic progenitors transduced with empty LXIΔN retroviral vector or with LMafBIΔN construct. (A) Histogram
displaying themRNA levels ofMMP9 and IL-7R genes (x-axis) detected, as relative quantity (RQ, y-axis) in hematopoietic progenitors over-expressingMafB cDNA (gray bars) as compared
to the empty LXIΔN retroviral vector (white bars). The data represent themean± s.e.m of six independent experiments. (B)Western blot analysis ofMAFB andMMP9 protein expression
was performed at day 14 of liquid culture (i.e. 10 days post-infection) on total extracts of transduced/NGFR puriﬁed cells. The analyzed protein and samples are respectively indicated on
the right and at the top of thepanel. Pro, Pro-peptide; Act, active. Expression of ACTINwas also analyzed to normalize the amounts of protein extract loaded in the various lanes. (C) Results
of ﬂow cytometry evaluation, performed to estimate IL-7R positivity in LMAFBIΔN-transduced cells as compared to the control sample infected with the empty vector (LXIΔN). Multi-
parameter ﬂow-cytometry analysis was used to assess IL-7R and NGFR expression in the indicated samples. The entities of surface antigen expression, measured as positive percentage,
are shown inside the blue square (LXIΔN) or red square (LMAFBIΔN).
Fig. 3. EMSA, ChIP and luciferase assays performed to validate MMP9MARE and IL-7RMARE binding elements. (A) Results of gel shift assays to evaluate theMafB in-vitro binding to the
putative MARE enhancers. As indicated in the table reported below the autoradiograms, lanes 1 and 2 represent the negative controls, i.e. the TNT Quick Master Mix incubated, respec
tively, with pcDNA3.1 empty vector, used as template, andwith the anti-FLAGM2 antibody. Lane 3 shows a shift complex (lower arrow) resulting by the incubation with “in vitro” tran
scribed/translated FlagMafB protein in the presence of [γ-32P]ATP-labeled probes. Lane 4 highlights a supershift complex (upper arrow) generated by the incubation of the same sample
with the anti-FLAGM2 antibody. (B) Chip experiment performed inhumannormalmonocytes to detect in-vivo binding ofMafB to the recognizedMARE elements. Immuno-precipitation
was conducted with an anti-Flag control Ab (CA, white bars) and a speciﬁc MafB Ab (MAFB, gray bars). Left panel, histogram showing the ratio between the amounts of PCR-ampliﬁed
MafB-bound DNA in ChIP samples and in input chromatin (% ChIP/INPUT). Right panel, ethidium gel images of semi-quantitative PCR of ChIP experiments. IC, Input Chromatin; CA, anti
Flag control antibody; MAFB, anti-MafB antibody. CTRL. REG., ampliﬁcation of the microsatellite region localized on chromosome 3 and selected as control. All ChIPs and semi
quantitative PCR were performed in triplicate; a representative experiment is shown. (C) Histograms describing the results of luciferase assays performed in HEK293 cells transfected
with the pT81Luc reporter plasmids and pcDNA3.1FlagMafB expression vector. x-axis, combination of transfected plasmids; y-axis,β-galactosidase normalized luciferase values. Bars rep
resent the mean luciferase activity ± s.e.m. of at least three independent experiments.
Fig. 1.Analysis ofMAFB,MMP9 and IL-7R gene co-expression in PMA treated THP1 cells. PMA stimulationwasperformedbyusing a 1.6 nMconcentration for 48h. (A)Histogramexhibiting
theMAFB,MMP9 and IL-7R transcript variations in PMA treated (gray bars) as compared to untreated cells (white bars). X-axis, gene symbol of the considered genes; y-axis, transcript
relative quantity (RQ). (B) Results of MAFB gene silencing leading to a down-regulation of both MMP9 and IL-7R gene expression. Gray bars indicate THP1 cells treated with MAFB
siRNA whereas white bars represent the cells treated with a control siRNA and used as calibrator sample. X-axis, gene symbol of selected genes; y-axis, transcript relative quantity
(RQ). (C) Western blot analysis showing MAFB, MMP9 and IL-7R down-regulation achieved in THP1 cells nucleofected with control siRNA (CONT) or siRNA targeting MafB (MAFB).
Normalization of protein extracts was achieved by VINCULIN expression. The protein name and the analyzed samples are indicated, respectively, on the right and at the top of the panel.
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959C. Gemelli et al. / Biochimica et Biophysica Acta 1843 (2014) 955–964THP1 monoblastic cells treated with phorbol 12-myristate 13-acetate
(PMA), a well-recognized in “vitro” model of monocyte–macrophage
differentiation. In this cell context, we analyzed the gene expression
variations of the investigated genes in two different experimental con-
ditions: PMA treatment and MafB gene silencing. The results achievedby QRT-PCR analysis demonstrated that, upon PMA exposure, THP1
cells exhibited a clear up-regulation of all transcripts (Fig. 1, panel A),
whereas MafB inhibition was coupled to a signiﬁcant reduction of the
selected genes expression both at mRNA (Fig. 1, panel B) and protein
levels (Fig. 1, panel C). The efﬁciency of gene silencing was veriﬁed by
Fig. 4.MAFB expression in human normal monocytes under polarization treatments. The
histograms report the mRNA expression levels of MAFB transcription factor and speciﬁc
macrophage polarization markers achieved in human monocytes untreated (white bars)
or stimulated (gray bars) with a combination of LPS and IFNγ ( A ), IL-4 (B) or IL-10
(C). Gene symbols are indicated on x-axis whereas mRNA levels, assessed through the
QRT-PCR reaction, are reported on y-axis as transcript relative quantity (RQ) (mean ±
s.e.m) of at least three independent experiments. (D)Western blot analysis of MAFB pro-
tein levels under the polarization conditions already explained above. Treatments and
proteins are respectively speciﬁed on the top and on the right of the panel. To normalize
the amounts of protein extract loaded in the various lanes, expression of ACTIN protein
was also included in this assay.
960 C. Gemelli et al. / Biochimica et Biophysica Acta 1843 (2014) 955–964QRT-PCR andWestern blotmethodologies and showed70% reduction of
MafB transcript (Fig. 1, panel B) and three fold down-regulation ofMafB
protein, as compared to the control siRNA (Fig. 1, panel C). Furthermore,
we performed a gene expression analysis of the considered genes in a
primary cell context over-expressing MafB. This assay was performed
in the macrophage progeny obtained from CD34+ hematopoietic
stem/progenitor cells retrovirally transducedwithMafB cDNA, obtained
as already described [5]. A set of experiments, carried out under these
conditions, highlighted that MafB over-expression is able to promote,respectively, a 3.5 ± 1.4 and 2.6 ± 0.7 (mean ± s.e.m) fold induction
of bothMMP9 and IL-7R transcripts, as compared to empty vector trans-
duced cells (Fig. 2, panel A). Accordingly, Western blot and ﬂow cytom-
etry analysis conﬁrmed MAFB over-expression and the consequent
MMP9 (Fig. 2, panel B) and IL-7R (Fig. 2, panel C) up-regulation in
LMafBIΔN-transduced progenitors as compared to the empty vector. Al-
together, these preliminary data further supported the involvement of
MafB in the transcriptional regulation ofMMP9 and IL-7R genes, indicat-
ing them as putative primary response genes of the considered TF.
3.2. Identiﬁcation of MARE elements in IL-7R and MMP9 promoter regions
To address this issue, we inspected IL-7R and MMP9 ﬂanking pro-
moter regions in order to identify putativeMafB binding sites. This anal-
ysis was carried out using the UCSC Genome Browser [28] and
considering two important criteria: 1) the possibility to identify ele-
ments with nucleotide divergency, since all several known MAREs are
different from the canonical consensus sequence [10]; and 2) a high
level of evolutionary conservation that is frequently associatedwith rel-
evant gene regulatory elements. Performing this investigation, a puta-
tive MARE element was recognized in each analyzed promoter region
and is speciﬁed in Table 1. To evaluate the capacity of MafB to bind
the identiﬁed motives we performed EMSA assays in a cell-free system,
based on the consideration that Maf is a heterogeneous protein family
[10], whose members are also expressed in myeloid cells [29,30], and
that the core region of MAREs may also be recognized by the nuclear
regulators of AP-1 family [10]. The results reported in Fig. 3, panel A,
showed that MMP9MARE and IL-7R MARE sequences were speciﬁcally
bound by the investigated TF (left panel). Inmore details, the two auto-
radiograms highlighted the appearance of a shift (lane 3, lower arrow)
and super-shift (lane 4, upper arrow) complex respectively in the pres-
ence of Flag–MafB protein and as a result of FLAG M2 antibody incuba-
tion. On the contrary, the double point mutated probes, investigated
with the same experimental design, did not exhibit such complexes
(right panel). These data were further validated by “in-vivo” chromatin
immuno-precipitation assay. Formaldehyde-cross linked chromatin
was extracted from human normal monocytes and then immuno-
precipitated with a speciﬁc anti-MafB or with an anti-Flag M2 Ab,
used as control. The histogram shown in Fig. 3, panel B reported the re-
sults (mean ± s.e.m.) obtained from three independent experiments,
exhibiting a clear enrichment of MafB-bound chromatin both in
MMP9 and in IL-7R promoter regions. Finally, to evaluate the capacity
of the isolatedMafB binding sites to activate transcription, luciferase re-
porter assays were performed. The obtained data are shown in Fig. 3,
panel C. The histograms display a signiﬁcant increase of luciferase activ-
ity in the presence of MafB protein as compared to the control samples,
represented by the responsive elements incubated with the empty vec-
tor pcDNA3.1. In these experiments, a basal transactivation activity was
also detected in the control samples and it was probably ascribed to the
capacity of AP-1 familymembers to recognize and bind the core regions
of the analyzed MARE elements. On the basis of this combined ap-
proach, it was possible to state that MMP9 and IL-7R are primary
response genes of MAFB TF.
3.3. Analysis of MafB expression in activated primary monocytes
Since the MMP9 gene is a well-recognized marker of the anti-
inﬂammatory process regulated by tissue macrophages, we focused
our attention on the role exerted by the considered TF in the macro-
phage polarization process. To this aim, we performed a preliminary
analysis of MafB expression in human normal monocytes treated with
the following agents: LPS plus IFNγ to achieve a classical activation;
IL-4 promoting an alternative activation; IL-10 inducing a macrophage
de-activating state [31]. The results of these experiments clearly dem-
onstrated that only IL-10 cytokine was able to induce MafB expression
up to a 5.0 ± 2.5 value (mean ± s.e.m; Fig. 4, panel C) whereas a
Fig. 5. Expression ofMafB andmacrophagepolarizationmarkers in response to IL-10 stimulation. The datawere achieved in humanmonocytes treatedwith a 50ng/ml concentration of IL-
10 cytokine. (A, B) QRT-PCR analysis to evaluate MafB, MMP9 and IL-7R transcript levels in IL-10 time course (A) or in MafB silencing experiments (B). Unstimulated monocytes (0H) or
samples treated with a non-targeting siRNA were used as detector respectively in panels A and B. The results are indicated on y-axis as transcript relative quantity (RQ) ± s.e.m. of three
independent replicates. (C)Western blot examination ofMAFB,MMP9, and IL-7R proteinswas carried out inmonocytes underMafB inhibition conditions. Combined treatments and pro-
tein names are speciﬁed at the top and on the right of the panel, respectively. To normalize the amounts of protein extract loaded in the various lanes, expression of ACTIN proteinwas also
included in this assay. (D, E) Gene expression analysis of CD163 andMRC1 genes reportedwith the samemodalities explained in panels A and B. (F) Flow cytometry evaluation to estimate
CD163 andMRC1 polarizationmarker expression inmonocytes undergoingMafB inhibition followed by IL-10 stimulation. The entities of surface antigen expression,measured as positive
percentage, are shown inside the dot plots.
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alternative activation. On the other hand, any MafB variation was
monitored upon LPS plus IFNγ stimulation (Fig. 4, panels A and B). To
validate the adopted experimental model, a similar analysis was
extended to well-recognized phenotypic markers, such as IL-6 and
TNFα for classical activation, IL-1RA and MRC1 for alternative activa-
tion, MRC1 and CD163 for the de-activation process and, as expected,
all of them exhibited an up-regulated expression upon treatment with
the corresponding agent (Fig. 4, panels A–C) [32–34]. To further support
this observation, we carried out aWestern blot analysis aimed to evalu-
ate MAFB protein levels under the experimental settings described
above, disclosing a remarkable increment of the studied TF upon expo-
sure of monocytes to IL-10 (Fig. 4, Panel D). It is therefore possible toconclude that MafB is involved in the transcriptional control of IL-10-
mediated macrophage polarization.
3.4. Analysis of MafB genetic program in IL-10 treated primary monocytes
Based on the data described thus far, we performed a set of time-
course experiments in which human primarymonocytes were exposed
to IL-10 in order to evaluate the expression pattern of MafB and its pri-
mary response genes in macrophage de-activation process. The out-
come of this investigation, reported as mean ± s.e.m. of three
independent stimulations, demonstrated that IL-10 is able to determine
a signiﬁcant induction of all the considered genes underlining, once
more, the existence of a clear correlation between MafB and its targets,
Table 2
Statistical analysis of “time-course experiments” performed in IL-10 treated monocytes.
p-Values
Treatment time 3 h 6 h 18 h 24 h 48 h
MAFB
Student's T-test 0.15 0.02 0.03 0.03 0.05
ANOVA analysis 0.00042677
MMP9
Student's T-test 0.04 0.07 0.09 0.001 0.08
ANOVA analysis 0.001044574
IL-7R
Student's T-test 0.07 0.23 0.04 0.11 0.13
ANOVA analysis 0.443383602
CD163
Student's T-test 0.18 0.03 0.01 0.06 0.10
ANOVA analysis 0.002228024
MRC1
Student's T-test 0.05 0.20 0.03 0.09 0.06
ANOVA analysis 0.000934677
Statistical analysis applied on gene expression data obtained in the “Time-course
experiments”was carried out in IL-10 stimulated humanmonocytes (see Fig. 5). Student's
T-test analysis was performed by comparing the value obtained in each treatment time
versus the untreated cells, used as baseline. Additionally, multiple comparison analysis
was carried out by one-way ANOVA and Newman–Keuls post hoc test and the results
are reported in the “Supplementary Material 2” ﬁle. Statistically signiﬁcant p-values
were reported in bold.
Fig. 6.Analysis ofMafB involvement in IL-10/STAT3 signaling pathway. (A) Schematic rep-
resentation of MafB promoter region showing the position of two putative STAT3 binding
sites (STAT3 enhancer 1 and STAT3 enhancer 2) from the transcription start site (TSS), in-
dicated by arrow. (B) Histogram displaying the results obtained by chromatin immuno-
precipitation experiments performed in IL-10 treated human monocytes and by using a
STAT3 or a Flag antibody as control. On x-axis, the combination of IL-10 stimulation and
antibodies used are indicated for both the investigated enhancers. On y-axis, the chroma-
tin enrichment is reported as the ratio between the amounts of PCR-ampliﬁed STAT3-
bound DNA in ChIP samples and in input chromatin (% ChIP/IMPUT). (C) The histogram
shows the data achieved by luciferase transactivation experiments performed in HEK-
293 cells. X-axis: combination of transfected plasmids; y-axis: β-galactosidase normalized
luciferase values. The results exhibited in panels B and C correspond to a mean value ±
s.e.m. of at least three independent experiments.
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rial 2 for Student's t-test, ANOVA and Newman–Keuls multiple compar-
ison post hoc tests). To further demonstrate the involvement of the
considered TF in IL-10 cellular response, MafB silencing experiments
were subsequently carried out on IL-10 treated human monocytes.
The histogram reported in Fig. 5, panel B, disclosed a clear MafB
down-regulation leading to a signiﬁcant inhibition of MMP9 mRNA,
that was also conﬁrmed by Western blot analysis (Fig. 5, panel C).
Under the same experimental conditions, IL-7R exhibited only a partial
down-regulation, detected both at transcriptional (Fig. 5, B) and at
translational level (Fig. 5, C). This ﬁnding allowed hypothesizing that
the genetic control exerted byMafB on this target gene is strong during
the up-regulation phase of its expression, while it ismarginal during the
maintenance of IL-7R basal levels, where other transcription factors are
probably involved. Finally, to better characterize the role played by
MafB TF in IL-10 anti-inﬂammatory state, we also analyzed CD163
and MRC1 expression. The data obtained display a clear induction
of CD163 and MRC1 upon IL-10 treatment (Fig. 5, panel D) and a
signiﬁcant down-regulation of both genes following MafB inhibition
(Fig. 5, panel E). Furthermore, by using a protocol for MRC1/CD163
biparametric ﬂow cytometry analysis, we also observed that MafB
down-regulation is able to determine a clear reduction of the double
positive cell population (Fig. 5, panel F). Taken together, these data
allowed us to conclude that MafB is involved in the transcriptional reg-
ulation of the macrophage de-activation process mediated by IL-10
enforcing, at the same time, it plays a role in the transcriptional regula-
tion ofMMP9 and IL-7R genes.3.5. MafB is a downstream target of the IL-10/STAT3 signaling pathway
To further support our ﬁndings, we analyzed the mechanistic corre-
lation between MafB and the intracellular signaling pathway activated
by IL-10. This immunosuppressive molecule exerts its effect by binding
to its receptor IL-10R, thereby activating the JAK1/STAT3 cascade.
[35,36]. As a consequence, we explored the possibility that the gene
coding for MafB could be a STAT3 direct target. In this regard, a prelim-
inary analysis of MafB promoter region, carried out using the UCSC ge-
nome browser [28], revealed the presence of two putative canonical
STAT3 motives (TTCCnGGAA), respectively, localized 9348 bp (STAT3enhancer 1) and 8805 bp (STAT3 enhancer 2) upstream the transcrip-
tion start site (TSS) (Fig. 6, panel A). These sites were subsequently val-
idated by ChIP and luciferase transactivation assays to verify the
capacity of the STAT3 TF to bind “in vivo” theMafB promoter region, de-
termining an up-regulation of its transcription and activity. ChIP exper-
iments were carried out in human monocytes exposed to IL-10
cytokine for 24 h and the results achieved demonstrated a speciﬁc inter-
action of STAT3 protein with the enhancer 1, whereas no binding
activity was detected on enhancer 2 (Fig. 6, panel B). To evaluate the
functional consequences of this ﬁnding, we subsequently performed a
luciferase transactivation assay using HEK293 cells ectopically trans-
duced with the pCMVSTAT3 vector, driving a constitutive expression
of the STAT3 protein, and the pT1Luc construct, in which the considered
enhancers had cloned upstream a luciferase reporter gene. In agree-
ment with ChIP experiments, the data obtained showed that STAT3 en-
hancer 1 was able to increase the luciferase activity as compared to
control cells whereas the enhancer 2 appeared devoid of any trans-
activation activity (Fig. 6, panel C). Globally, in light of these results, it
is possible to conclude thatMafB is a STAT3 target gene and it is a down-
stream effector of the IL-10/STAT3 signaling pathway involved in the
macrophage de-activation process.
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A number of reports have demonstrated the crucial role played by
MafB in the transcriptional control ofmonocyte–macrophage differenti-
ation [5,6,14,15] and the experimental activity developed in our labora-
tory has signiﬁcantly contributed to such studies, providing a global
view of the genetic program activated by this TF during the mentioned
process [5]. In spite of this effort, little is to date known about MafB di-
rect targets that could be responsible for its biological effects. Using a
combined approach of gene function studies and DNA–protein interac-
tion analysis that were mainly conducted in human primary macro-
phages, we have been able to demonstrate that IL-7R and MMP9 are
primary response genes ofMafB TF. Although IL-7R has been often asso-
ciated with T lymphocyte biology in the past [37–39], our results have
assigned a novel biological meaning to this receptor and, accordingly,
to its ligand. Our previous observations highlighted a strong correlation
between MafB and IL-7R, showing that primary human monoblasts ex-
press high mRNA levels of both genes [14]. In addition, published stud-
ies have recently indicated that IL-7 is able to promote the
differentiation of macrophages to dendritic [40] and osteoclast cells
[41,42], i.e. further specialized cell contexts belonging to the same line-
age. These considerations put in clear evidence the importance of the
molecular mechanism arising by our data and support the idea that IL-
7R plays an important role inmonocyte differentiation andmacrophage
activation. MMP9 is a well-known protein, implicated in the process of
extracellular matrix remodeling, sustained by tissue macrophages.
In this regard, a large body of evidence underlined the functional
correlation between MMP9 and the “Tumor-Associated Macrophages”
(TAMs), themajor inﬂammatory component of stroma in many tumors
[21,22,43], leading to the hypothesis that MafB might regulate the bio-
logical functions exerted by these cells.
The relevance of the results presented in this report also resides in
some strictly molecular aspects concerning the nucleotide composition
and spatial organization of MARE motives. In fact, the identiﬁcation of
MARE elements has appeared quite complicated for the following
reasons: 1) binding sites, belonging to this category and isolated so far
[44–46], are divergent from the canonical consensus TGCTGAC/
GTCAGCA indicated in the scientiﬁc literature; 2) a sequence matrix
describing virtually all nucleotide combinations in each position of the
MARE element has not been deﬁned yet; and 3) all members of the
AP-1 family recognize the highly conserved TGAC/GTGA core region,
but the ﬂanking nucleotides conferring binding speciﬁcity to single
Maf proteins have still been poorly characterized and may exhibit a
signiﬁcant reciprocal divergence. Based on these considerations, our
data will allow a better comprehension of the MARE structure.
Additional experiments described in our paper also disclosed an
involvement of MafB in the transcriptional regulation of macrophage
polarization,where it is shown toplay a role in the de-activation process
induced by the IL-10 cytokine.Macrophage activationmaybe deﬁned as
a functional specialization acquired by tissue resident macrophages in
response to extracellular or intracellular signals and represents a
complex process during which macrophages display a large spectrum
of functional phenotypes implying a remarkable plasticity [31,47,48].
In this context, macrophage de-activation is an active phenomenon
able to switch off both classical and alternative activation. IL-10, togeth-
er with glucocorticoids and TGFβ, is one of the main regulators of this
anti-inﬂammatory response [33,49], being able to limit the entity and
duration of inﬂammation and to promotewound healing, tissue remod-
eling and the restoration of tissue homeostasis. Cellular response to IL-
10 stimulation is mediated by the activation of JAK1 kinase, leading to
phosphorylation and activation of the STAT3 transcription factor that,
in turn, induces the expression of several polarization markers and
other TFs [36,49]. Our data demonstrated, for the ﬁrst time, that STAT3
is able to up-regulate MafB expression through a direct transcription
mechanism and that treatment of macrophages with IL-10 stimulates
this effect. This ﬁnding allow us to hypothesize the existence of asignaling cascade by which stimulation of macrophages with IL-10 de-
termines a sequential activation of STAT3 and MafB, resulting in the
up-regulated expression of MMP9 and IL7R genes. The ﬁnal effect of
this regulatory pathway would be to resolve the inﬂammatory condi-
tion and to restore tissue integrity.
In conclusion, the data reported here represent, in our opinion, a
clear demonstration supporting the involvement of MafB in IL-10medi-
ated macrophage de-activation. More in general, these results also con-
tribute to shed light on the molecular mechanisms regulating the
macrophage polarization process.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.01.021.
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